The U.S. Food and Drug Administration (FDA) on Wednesday approved Pfizer Inc.’s PFE TUKYSA (tucatinib) in combination with ...
The HER2CLIMB-05 trial is a randomized, double blind, placebo-controlled, pivotal Phase 3 study evaluating the efficacy and safety of TUKYSA compared to placebo, both in combination with trastuzumab ...
Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or ...
Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, ...
Pfizer said the Food and Drug Administration approved Tukysa as a front-line maintenance treatment for people with a form of breast cancer.
If you've been looking for high-yield stocks, Pfizer (PFE-1.40%) may have crossed your radar screen. As shares of the pharma ...
Pfizer (NYSE:PFE) raised its revenue guidance in the second quarter of 2026, held its earnings guidance and announced another round of cost cuts. It also reported a loss of $0.04 a share.
Key TakeawaysVaxcyte’s VAX-31 matched Pfizer’s Prevnar 20 on all 20 shared serotypes and Merck’s Capvaxive on 17 of 19 in a 4,047-person Phase 3 trial. Prevnar brought in $6.
ROME, Oct 7 (Reuters) - Pfizer will cut around 330 jobs in Italy at its Sicily plant, labour unions said on Wednesday, making ...
The crowd is looking at the next couple of years. It should be looking five years into the future.
Pfizer's revenue over the past twelve months was 0.2% lower than a year earlier. When sales are flat, look at what management ...
NEW YORK-- (BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results